Abemaciclib: A review of the evidence through clinical cases
There is no excerpt because this is a protected post.
What is new in endocrine therapy in cancer? Read our endocrine therapy blog and learn more about the latest advancements in endocrine therapy for several cancers, including breast cancer and prostate cancer.
Breast cancer update January 2021
With the San Antonio Breast Cancer Conference (SABCS) 2020 by AACR just completed, several new and clinical relevant phase 2 and phase 3 have been published in the Journal of the American Medical Association, Clinical Cancer Research, New England Journal of Medicine, Journal of Clinical Oncology, and Lancet Oncology. [‘mediPr] provides you with an overview.
ASCO 2020 Lung, Breast, and Liver Cancer Update
This year, ASCO 2020 was held as a virtual conference due to the COVID-19 pandemic. This is a summary of key trials presented at ASCO, focusing primarily on breast cancer, liver cancer, and lung cancer.
Capivasertib added to fulvestrant improves progression-free survival in advanced breast cancer patients
Adding capivasertib to fulvestrant improves the progression-free survival (PFS) in postmenopausal women with oestrogen receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative, advanced breast cancer resistant to aromatase inhibitors, concluded Jones et al. (2020) in Lancet Oncology.
Ribociclib plus Fulvestrant Improves Survival in Advanced Breast Cancer
In patients with hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer, adding ribociclib to fulvestrant improved the overall survival (OS) by 28% compared to fulvestrant alone, as reported by Slamon et al. (2019) in The New England Journal of Medicine.
Palbociclib approved for the treatment of male breast cancer
On 4 April 2019, the US FDA approved palbociclib (Ibrance®, Pfizer) plus aromatase inhibitor or fulvestrant for the treatment of male patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer.
Ribociclib FDA label updated to include pre- and perimenopausal women
On July 18, 2018, the US FDA expanded the ribociclib (Kysqali©, Novartis) approval. Ribociclib plus an aromatase inhibitor as initial endocrine-based therapy is no longer limited to postmenopausal HR-positive, HER2-negative advanced or metastatic breast cancer patients alone and now includes pre- and perimenopausal women. Furthermore, the FDA has added the combination ribociclib plus fulvestrant as initial endocrine-based therapy for postmenopausal women with HR-positive, HER2-negative advanced or metastatic breast cancer.
Enzalutamide FDA approved for castration-resistant prostate cancer (CRPC)
On July 13, the FDA approved enzalutamide (Xtandi©, Astellas), for use in patients with castration-resistant prostate cancer (CRPC).
Luminal Breast Cancer: can CDK4/6 Inhibition by Palbociclib Improve on Chemotherapy?
Can chemotherapy be avoided in women with hormone-sensitive breast cancer? This is a prominent question in the treatment of breast cancer around the globe.
Should all Women with Endocrine-Sensitive and Operable Breast Cancer Receive Adjuvant Hormonal Therapy?
One in six women with early, operable breast cancer may not need years of adjuvant hormonal therapy after primary treatment. This was the conclusion of a recent study published in JAMA (the Journal of the American Medical Association) Oncology.
ESMO16 Breast Cancer: Palbociclib, Ribociclib and Abemaciclib Data
Cyclin-dependent Kinase 4 and 6 (CDK4/6) inhibitors have shown clinical activity in patients with endocrine-resistant metastatic breast cancer. During the European Society for Medical Oncology (ESMO) Annual Meeting 2016, significant updates on studies with CDK4/6 inhibitors ribociclib, palbociclib and abemaciclib were presented.